Table 2.
Response to lenalidomide and low-dose dexamethasone
| All patients (N = 90) (%) | |
|---|---|
| Continuing treatment | 20 (22) |
| Discontinued treatment | |
| Failure to achieve ≥ PR after 4 cycles | 6 (7) |
| Progression | 40 (44) |
| Drug-related adverse event | 15 (17) |
| Death | 4 (4) |
| Follow-up loss | 3 (3) |
| ASCT | 2 (2) |
| Response | |
| Overall response | 72 (80) |
| VGPR or greater | 40 (44) |
| CR | 22 (24) |
| VGPR | 18 (20) |
| PR | 32 (36) |
| SD | 7 (8) |
| PD | 9 (10) |
| NA | 2 (2) |
Administered cycles, median (range): 11 cycles (1–24)
ASCT autologous stem cell transplantation, CR complete response, NA not available, PD progressive disease, PR partial response, SD stable disease, VGPR very good partial response